In this article
MEDVi QUAD is marketed for erectile dysfunction, not weight loss. The current product page we reviewed lists apomorphine, L-citrulline, sildenafil, and tadalafil. It advertises a compounded combination, so a familiar ingredient name does not establish that the complete product has FDA approval.
Whether the product is appropriate for you requires a clinician who knows your medical history and every medicine you take. This article identifies questions and source limitations; it does not endorse combining these ingredients or give instructions for taking them.
We cannot establish that MEDVi QUAD is safe for an individual. Its current page lists four ingredients, including both sildenafil and tadalafil. A clinician must assess the complete combination and interactions; ingredient-level evidence is not approval of the compounded product.
What to know first
- The reviewed current page lists apomorphine, L-citrulline, sildenafil, and tadalafil.
- Sildenafil and tadalafil have important interactions, including nitrates and riociguat.
- Ask about the complete compounded formula and avoid adding another ED medicine on your own.
Use the current ingredient list, not a search snippet
The official QUAD page names apomorphine, L-citrulline, sildenafil, and tadalafil and advertises a price of $9 per dose. That is a marketing statement from the product page, not a complete individualized prescription or proof of the total purchase cost.
Other online descriptions can list different ingredients or discuss other ED products. Do not assume they describe the formulation currently proposed to you. Ask the prescriber and pharmacist for the exact ingredients, amounts, route, and instructions on the actual order.
The combination needs its own assessment
Sildenafil and tadalafil are both PDE5 inhibitors. Their individual medication references include warnings and interactions; those references do not establish the safety or effectiveness of combining them in a four-ingredient compounded preparation.
Do not add another ED drug, borrow a dose, or combine the product with other performance products without the prescribing clinician’s explicit assessment. A claim that multiple ingredients work together is not a substitute for evidence about the exact formulation and the person receiving it.
Important interaction questions
Tell the clinician if you use nitrate medicines for chest pain or recreational nitrites, sometimes called poppers, or take riociguat. Sildenafil and tadalafil medication information warns against these combinations because of the risk of a dangerous drop in blood pressure. Also disclose alpha blockers, blood-pressure medicines, other ED treatments, and all supplements.
Discuss cardiovascular conditions, fainting or low blood pressure, and relevant kidney, liver, vision, or hearing history. A clinician should evaluate whether sexual activity and the proposed treatment are appropriate. This list is not exhaustive and is not a do-it-yourself eligibility test.
Know when to obtain medical help
The medication information describes serious symptoms requiring urgent attention, including a prolonged erection lasting more than four hours, sudden vision or hearing changes, or severe symptoms such as chest pain or fainting. Seek appropriate urgent or emergency care instead of waiting for a routine support reply.
Tell the treating professional the exact product and when it was taken. In particular, do not self-treat chest pain with a nitrate after an ED medicine; get emergency advice and make the ED medication exposure clear to the care team.
What to verify before purchase
Ask which pharmacy prepares the product, what clinical reason supports the combination for you, which alternatives were considered, and how adverse effects will be handled. A compounded medicine is not FDA-approved, even if an individual component is present in approved drugs.
The QUAD page lists +1 (585) 312-4226 as its contact number. Our MEDVi phone-number guide distinguishes this from general brand support. Confirm the current product-specific terms, total charge, and refund rules rather than importing the weight-loss program’s policies.
Keep the wider brand context separate
The FDA’s February 2026 warning letter to MEDVi concerns the compounded GLP-1 marketing described in that letter. It should be read as important brand context, but not represented as an FDA clinical evaluation of QUAD.
See the MEDVi company review for that record. The key medical question here remains the exact ED formulation and its suitability for your own circumstances.
Sources & research notes
Checked September 21, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.
- MEDVi QUAD: product and ingredient pageProvider-published information · Checked September 21, 2026
- MedlinePlus: sildenafilMedical reference · Checked September 21, 2026
- MedlinePlus: tadalafilMedical reference · Checked September 21, 2026
- FDA: risks of compounded drugsRegulatory / public agency · Checked September 21, 2026
- FDA: MEDVi warning letter, February 20, 2026Regulatory / public agency · Checked September 21, 2026
Read our methodology · Commercial disclosure · Request a correction